Clinical trials are currently ongoing to evaluate the utility of antibodies against programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) as monotherapy or combination therapy in patients with hepatocellular carcinoma (HCC). Results of combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab in HCC were presented at the 2017 annual meeting of the ASCO (American Society of Clinical Oncology). Response rates were 25% in all 40 patients and 40% in the 20 uninfected patients, both of which are encouraging. Transcatheter arterial chemoembolization and radiofrequency ablation can activate tumor immunogenicity by releasing tumor-associated antigen and by inducing the migration of cytotoxic T lymphocytes to small intrahepatic metastatic nodules. Subsequent administration of anti-PD-1 antibody could control these small intrahepatic metastatic nodules. In a nonclinical study, the combination of pembrolizumab and lenvatinib inhibited the cancer immunosuppressive environments induced by tumor-associated macrophages and regulatory T cells. This, in turn, decreased the levels of TGF-β and IL-10, the expression of PD-1, and the inhibition of Tim-3, triggering anticancer immunity mediated by immunostimulatory cytokines such as IL-12. Studies such as these may provide insight into the appropriate molecular targeted agents to be used with immune checkpoint inhibitors.

Keywords:
Hepatocellular carcinoma, Nivolumab, Pembrolizumab, Ipilimumab, Tremelimumab
1.
Chen DS, Mellman I: Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10.
2.
Sznol M, Chen L: Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013;19:1021-1034.
3.
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-567.
4.
Shih K, Arkenau HT, Infante JR: Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014;74:1993-2013.
5.
Philips GK, Atkins M: Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol 2015;27:39-46.
6.
Mahoney KM, Freeman GJ, McDermott DF: The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 2015;37:764-782.
7.
Harshman LC, Drake CG, Wargo JA, Sharma P, Bhardwaj N: Cancer immunotherapy highlights from the 2014 ASCO Meeting. Cancer Immunol Res 2014;2:714-719.
8.
Topalian SL, Drake CG, Pardoll DM: Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207-212.
9.
Merelli B, Massi D, Cattaneo L, Mandala M: Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014;89:140-165.
10.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-2520.
11.
Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al: Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013;49:2233-2242.
12.
Ribas A: Tumor immunotherapy directed at PD-1. N Engl J Med 2012;366:2517-2519.
13.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-144.
14.
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
15.
Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al: Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009;15:971-979.
16.
El-Khoueiry AB, Melero I, Crocenzi TS, et al: Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015;33(suppl; abstr LBA101). http://meetinglibraryascoorg/slides.
17.
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-2502.
18.
Todd SC, El-Khoueiry AB, Yau T, Melero I, Sangro B, Kudo M, et al: Nivolumab in sorafenib-naive and -experienced patients with advanced hepatocellular carcinoma: CheckMate040 Study. J Clin Oncol 2017;35(15 suppl):4013.
19.
Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P, et al: A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-88.
20.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
21.
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-2017.
22.
Kudo M: Molecular targeted agents for hepatocellular carcinoma: current status and future perspectives. Liver Cancer 2017;6:101-112.
23.
Kelley RK, Abou-Alfa GK, Bendell JC, Kim TY, Borad MJ, Yong WP, et al: Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma(HCC): phase I safety and efficacy analyses. J Clin Oncolol 2017;35(suppl; abstr 4073).
24.
Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al: Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-551.
25.
Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, et al: Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011;54:532-540.
26.
Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al: Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344-1354.
27.
Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-1554.
28.
Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, et al: Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol 2015;50:191-202.
29.
Kudo M: Locoregional therapy for hepatocellular carcinoma. Liver Cancer 2015;4:163-164.
30.
Kudo M: Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer 2015;4:39-50.
31.
Tsurusaki M, Murakami T: Surgical and locoregional therapy of HCC: TACE. Liver Cancer 2015;4:165-175.
32.
Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, et al: Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer 2015;4:253-262.
33.
Teng W, Liu KW, Lin CC, Jeng WJ, Chen WT, Sheen IS, et al: Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation. Liver Cancer 2015;4:26-38.
34.
Kang TW, Rhim H: Recent advances in tumor ablation for hepatocellular carcinoma. Liver Cancer 2015;4:176-187.
35.
Lencioni R, de Baere T, Martin RC, Nutting CW, Narayanan G: Image-guided ablation of malignant liver tumors: recommendations for clinical validation of novel thermal and non-thermal technologies - a Western perspective. Liver Cancer 2015;4:208-214.
36.
Kudo M: Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials. Oncology 2017;92(suppl 1):50-62.
37.
Mizukoshi E, Yamashita T, Arai K, Sunagozaka H, Ueda T, Arihara F, et al: Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 2013;57:1448-1457.
38.
Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, et al: Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer 2016;5:190-197.
39.
Ho MC, Hasegawa K, Chen XP, Nagano H, Lee YJ, Chau GY, et al: Surgery for intermediate and advanced hepatocellular carcinoma: a consensus report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer 2016;5:245-256.
40.
Kudo M: Molecular targeted therapy for hepatocellular carcinoma: where are we now? Liver Cancer 2015;4:I-vii.
41.
Zhang B, Finn RS: Personalized clinical trials in hepatocellular carcinoma based on biomarker selection. Liver Cancer 2016;5:221-232.
42.
Tiegs G, Lohse AW: Immune tolerance: what is unique about the liver. J Autoimmun 2010;34:1-6.
43.
Kudo M: Immune checkpoint blockade in hepatocellular carcinoma. Liver Cancer 2015;4:201-207.
44.
Kato T, Bao X, Macgrath S, Tabata K, Hori Y, Tachino S, et al: Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response. Ann Oncol 2016;27(suppl_6):2PD.
45.
Makker V, Rasco DW, Dutcus CE: A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma. J Clin Oncol 2017;35(suppl; abstr 5598).
46.
Sharma P, Allison JP: Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015;161:205-214.
47.
Sharma P, Allison JP: The future of immune checkpoint therapy. Science 2015;348:56-61.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.